AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$ONC

Dugan Margaret sold $66K of ONC

Dugan Margaret sold 212 shares of BeOne Medicines Ltd. (ONC) at $309.60 on 2026-05-22.

Original reporting
SEC EDGAR · Dugan Margaret
Published May 27, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Bearish
medium confidence
Mentioned
$ONC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCBearishLow
01

Why it matters

Insider selling disclosures can modestly affect near-term sentiment, but this filing lacks any operational or clinical catalyst.

02

Market read

Traders may monitor for insider activity patterns, but this specific sale is unlikely to drive a major repricing without additional company news.

03

What to watch

The trade size is small relative to typical biotech float; without follow-on purchases/sales or a pattern, signal-to-noise is low.

Relevance 6/10Timing: Immediate for sentiment/positioning; limited for fundamental repricing.

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCBearishMedium confidence
Context

Director Dugan Margaret filed an open-market sale of 212 ONC shares for ~$65.6K, leaving 0 shares after the trade.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment/flow effects.

Evidence & confidence

The filing is an SEC Form 4 insider sale (no 10b5-1 plan stated) but the size is small and there is no accompanying company-specific news (earnings, trial, deal, or guidance).

Market effects

Sector

Minimal; single-insider sale does not indicate sector-wide regulatory or clinical changes.

Regional

None indicated; filing is company-specific and US SEC disclosure.

Global

None indicated; no cross-border deal/trial/regulatory event mentioned.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification; the absence of a 10b5-1 plan does not necessarily imply negative information.

Key entities

  • insider
    Dugan Margaret

    Director who sold 212 ONC shares in an open-market transaction.

  • issuer
    BeOne Medicines Ltd.

    Issuer of ONC shares; director sale disclosed via SEC Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min